Osteoclast-Cancer Cell Metabolic Symbiosis Renders PARP Inhibitor Therapy Resistance in Bone Metastasis
H. Fan, Z. Xu, K. Yao, B. Zheng, Y. Zhang, X. Wang, T. Zhang, X. Li, H. Hu, B. Yue, Z. Hu, H. Zheng
This study identifies a metabolic symbiosis between osteoclasts and cancer cells in bone metastasis that contributes to PARP inhibitor resistance, showing that targeting this interaction with PARPi and zoledronate can synergistically reduce metastasis.
bioRxiv · Aug 15, 2023 · PreprintCancer Biology